151 related articles for article (PubMed ID: 17512703)
21. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers.
Fuchs PC; Barry AL; Brown SD
Antimicrob Agents Chemother; 2001 Jun; 45(6):1915-8. PubMed ID: 11353653
[TBL] [Abstract][Full Text] [Related]
22. Carbapenems in the USA: focus on doripenem.
Lister PD
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):793-809. PubMed ID: 17914914
[TBL] [Abstract][Full Text] [Related]
23. Lyme disease: disparity between culture and polymerase chain reaction detection of Borrelia burgdorferi after exposure to ceftriaxone in vitro.
Varde S; Wormser GP; Nowakowski J; Nadelman RB; Bittker S; Cooper D; Schwartz I
Conn Med; 1999 Oct; 63(10):589-91. PubMed ID: 10578549
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Cha R
Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease.
Pavia CS; Wormser GP; Nowakowski J; Cacciapuoti A
Antimicrob Agents Chemother; 2001 Mar; 45(3):936-7. PubMed ID: 11181384
[TBL] [Abstract][Full Text] [Related]
26. [Borrelia burgdorferi Group: in-vitro antibiotic sensitivity].
Henneberg JP; Neubert U
Orv Hetil; 2002 May; 143(21):1195-8. PubMed ID: 12073540
[TBL] [Abstract][Full Text] [Related]
27. In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa.
Kanellakopoulou K; Sarafis P; Galani I; Giamarellou H; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2008 Jul; 32(1):33-9. PubMed ID: 18538547
[TBL] [Abstract][Full Text] [Related]
28. Activity of a novel carbapenem, doripenem, against anaerobic pathogens.
Goldstein EJ; Citron DM
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):447-54. PubMed ID: 19249176
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi.
Hunfeld KP; Weigand J; Wichelhaus TA; Kekoukh E; Kraiczy P; Brade V
Int J Antimicrob Agents; 2001 Mar; 17(3):203-8. PubMed ID: 11282265
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria.
Peeters E; Nelis HJ; Coenye T
J Antimicrob Chemother; 2009 Oct; 64(4):801-9. PubMed ID: 19633000
[TBL] [Abstract][Full Text] [Related]
31. Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.
Hunfeld KP; Brade V
Wien Klin Wochenschr; 2006 Nov; 118(21-22):659-68. PubMed ID: 17160604
[TBL] [Abstract][Full Text] [Related]
32. Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae.
Hovde LB; Rotschafer SE; Ibrahim KH; Gunderson B; Hermsen ED; Rotschafer JC
Diagn Microbiol Infect Dis; 2003 Apr; 45(4):265-7. PubMed ID: 12729997
[TBL] [Abstract][Full Text] [Related]
33. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species.
Lai CC; Tan CK; Lin SH; Liao CH; Chou CH; Hsu HL; Huang YT; Hsueh PR
J Antimicrob Chemother; 2009 Jul; 64(1):73-8. PubMed ID: 19398458
[TBL] [Abstract][Full Text] [Related]
34. Use of Carbapenems against clinical, nontyphoid Salmonella isolates: results from in vitro and in vivo animal studies.
Tang HJ; Chen CC; Zhang CC; Cheng KC; Chiang SR; Chiu YH; Ku YH; Ko WC; Chuang YC
Antimicrob Agents Chemother; 2012 Jun; 56(6):2916-22. PubMed ID: 22470122
[TBL] [Abstract][Full Text] [Related]
35. Susceptibilities of Propionibacterium acnes ophthalmic isolates to ertapenem, meropenem, and cefepime.
Shames R; Satti F; Vellozzi EM; Smith MA
J Clin Microbiol; 2006 Nov; 44(11):4227-8. PubMed ID: 16971643
[TBL] [Abstract][Full Text] [Related]
36. An in vitro study of the activity of telithromycin against mobile and cystic forms of Borrelia afzelii.
Brorson Ø; Brorson SH
Infection; 2006 Feb; 34(1):26-8. PubMed ID: 16501899
[TBL] [Abstract][Full Text] [Related]
37. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
[TBL] [Abstract][Full Text] [Related]
38. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Snydman DR; Jacobus NV; McDermott LA
Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
[TBL] [Abstract][Full Text] [Related]
39. Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates.
Hunfeld KP; Kraiczy P; Wichelhaus TA; Schäfer V; Brade V
Int J Antimicrob Agents; 2000 Jun; 15(1):11-7. PubMed ID: 10856671
[TBL] [Abstract][Full Text] [Related]
40. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.
Dever LL; Jorgensen JH; Barbour AG
J Clin Microbiol; 1992 Oct; 30(10):2692-7. PubMed ID: 1400969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
